Veru (NASDAQ:VERU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Veru (NASDAQ:VERU) from a sell rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

Several other brokerages have also issued reports on VERU. Weiss Ratings lowered Veru from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Canaccord Genuity Group reissued a “buy” rating and set a $25.00 price objective on shares of Veru in a research note on Thursday, June 4th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Veru presently has a consensus rating of “Hold” and an average price target of $24.50.

Veru Trading Up 1.2%

Shares of NASDAQ VERU opened at $2.44 on Friday. The firm has a market cap of $41.60 million, a PE ratio of -3.54 and a beta of -1.17. The company has a fifty day moving average price of $2.49 and a 200 day moving average price of $2.52. Veru has a 1-year low of $2.05 and a 1-year high of $7.33.

Veru (NASDAQ:VERU) last posted its earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. Equities research analysts forecast that Veru will post -1.07 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new position in Veru during the 2nd quarter worth $328,000. Renaissance Technologies LLC bought a new position in Veru in the first quarter worth about $153,000. Finally, Royal Bank of Canada lifted its position in Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after acquiring an additional 5,008 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.